This guide reviews effective programs and practices to prevent HIV and increase adherence to and retention in care (SAMHSA)
Bibliography: Interventions – Harm Reduction
The Global State of Harm Reduction 2020
The Global State of Harm Reduction is the only report that provides an independent analysis of harm reduction in the world (Harm Reduction International)
How to use the ASSIST-Lite screening tool to identify alcohol and drug use and tobacco smoking
Health and social care professionals are well placed to provide interventions targeted at all substances. This tool will help you to identify risky drug and alcohol use and tobacco smoking, and respond in an evidence-based way. This will contribute to reducing premature mortality and morbidity (PHE)
Characteristics of people who used the Melbourne and Sydney medically supervised injecting facilities surveyed in the Illicit Drug Reporting System 2019
In this bulletin, we summarise findings from the Sydney and Melbourne survey samples who report use of the supervised injecting facilities in their city (NDARC)
Expanded Access to Naloxone Can Curb Opioid Overdose Deaths
Changes to prescribing laws to improve availability of the overdose reversal drug can reduce fatalities (PEW)
The impact of arrest and seizure on drug crime and harms: A systematic review
Drawing on the Global Policing Database (GPD), this review assesses the impact of supplier arrests and seizures on drug crime, drug use, drug price, drug purity, and drug harm outcomes (Australian Crime Commission)
EMCDDA releases study findings on the impact of COVID-19 on drug markets, use and services in the eastern ENP region
The expansion of contactless drug dealing, the increase in the use of licit drugs and the adaptation of drug treatment protocols during lockdown are among the findings highlighted today in a new EMCDDA report: Impact of COVID-19 on drug markets, drug use, drug-related harms and responses in east European Neighbourhood Policy countries
COVID-19: guidance for commissioners and providers of services for people who use drugs or alcohol
This guidance outlines COVID-19 advice for commissioners and service providers involved in assisting people who are dependent on drugs or alcohol or both (Public Health England)
Preventable injecting-related injuries and diseases reported by many people who inject drugs
In a new report by researchers at the National Drug and Alcohol Research Centre (NDARC), UNSW Sydney, data from 897 face-to-face interviews with PWID from the 2019 Illicit Drug Reporting System (IDRS) were analysed
Recreational cannabis regulation and harm reduction
BERL advice to the Ministry of Justice (New Zealand)
Support and informational needs of ‘at-risk’ groups highlighted in new SDF report
A new report that identifies specific risks and informational needs of certain ‘at-risk’ groups in Scotland has been published today by Scottish Drugs Forum
Does it matter where you get medication for opioid use disorder? A comparison of three types of clinics
Do substance-related outcomes vary across different types of community clinics? (Recovery Research Institute)
Substance use disorder recovery – there’s an app for that… but who uses it and who benefits?
To begin to address this gap in the clinical literature, the authors conducted an analysis of Sober Grid, a popular substance use disorder (SUD) recovery smartphone application (Recovery Research Institute)
Managing drug and alcohol misuse at work
Our report, written with input from charities and experts in the space, examines the management and prevention of drug and alcohol misuse at work (CIPD)
Overdose Education and Naloxone Distribution Within Syringe Service Programs — United States, 2019
In 2019, among 263 SSPs responding to an online survey, 247 (94%) had implemented OEND. The number of persons who received naloxone per opioid overdose death and the number of naloxone doses distributed per opioid overdose death during the previous year varied by census division (CDC)
Access to take-home naloxone increased through paramedic supply
Ambulance paramedics are to supply to patients at risk of an opiate overdose take-home naloxone as part of a pilot scheme in Glasgow (SDF)
National Naloxone programme Scotland
This release by Public Health Scotland presents information on the number of take-home naloxone kits issued by the National Naloxone Programme in Scotlan
Physicians’ progress toward ending the nation’s drug overdose and death epidemic
The nation’s continuing increase in drug overdoses is fuelling the evolution of a more dangerous and complicated epidemic (AMA)
Scottish Drug Deaths Taskforce: One Year Report
This report details the work and achievements of the Drug Deaths Taskforce following its establishment in July 2019
Injecting equipment provision in Scotland
This release by Public Health Scotland presents information on the provision of injecting equipmen
Medicinal Use of Psilocybin: Reducing restrictions on research and treatment
The Adam Smith Institute, in conjunction with the Conservative Drug Policy Reform Group (CDPRG), has published a new report outlining the medical potential of psilocybin and the need to reduce restrictions on research and treatmen
A national model of remote care for assessing and providing opioid agonist treatment during the COVID-19 pandemic: a report
This report describes the development of a national model of remote care to eliminate waiting lists and increase access to OAT in Ireland (BMC)
Summing it up: Building evidence to inform advocacy for harm reduction funding in Asia
Harm Reduction International developed tools for assessing national harm reduction investment and spending on drug law enforcement. This report presents the research findings generated by these tools in seven Asian countries. It provides insights on the state of harm reduction financing, informed by donor and government stakeholders, civil society and community representatives (HRI)
Saving Lives in the time of COVID-19
Case Study of Harm Reduction, Homelessness and Drug Use in Dublin, Ireland (LSE)
Key findings from the ‘Australians’ Drug Use: Adapting to Pandemic Threats’ (ADAPT) Study
The Australians’ Drug Use: Adapting to Pandemic Threats (ADAPT) Study is exploring the short and long-term impact of the COVID-19 pandemic on the experiences of Australians who use illicit drugs (NDARC)
Drugs, Prisons and ‘Unintended Consequences’ – Does drug interdiction drive drug-related harms?
The availability and use of drugs in prisons cannot be separated from wider drug policy. The criminalisation of drugs and the people who use or sell them fuels mass incarceration in many countries, and in doing so creates large profitable markets for drugs behind bars (Gdpo)
Impacts of COVID-19 and associated restrictions on people who use illicit stimulants in Australia
Preliminary findings from the Ecstasy and Related Drugs Reporting System 2020 (NDARC)
Original quantitative research – Setting the baseline
A description of cannabis poisonings at a Canadian pediatric hospital prior to the legalization of recreational cannabis (Public Health Agency of Canada)
Trends in awareness, uptake and deployment of naloxone among a sample of people who inject drugs in Australia
This bulletin describes the awareness of naloxone and the take-home naloxone program in Australia, both nationally and by jurisdiction. It also explores access, use and acceptance of naloxone, and examines demographic differences for these aspects (NDARC)
Adulterants, Contaminants and Co-occurring Substances in Drugs on the Illegal Market in Canada
Provides a snapshot of the contents of drugs on the illegal market in Canada using 2018–2019 data from drug seizures, drug checking services and a drug monitoring study. This bulletin is accompanied by a technical report featuring detailed research methods and data PDF (CCENDU )
COVID-19: guidance for commissioners and providers of services for people who use drugs or alcohol
This guidance outlines COVID-19 advice for commissioners and service providers involved in assisting people who are dependent on drugs or alcohol or both (PHE)
Assessing the Evidence on Supervised Drug Consumption Sites
This working paper assesses evidence on and arguments made about supervised consumption sites (RAND)
Clinical guidelines for use of depot buprenorphine (Buvidal® ) in the treatment of opioid dependence (PDF)
This Clinical Guideline has been developed to inform decision-making by clinicians prescribing and/or patients being treated with Buvidal® long-acting injected buprenorphine preparations (SMMGP)
Novel benzodiazepines: prevalence and harms in the UK
This report examines the evidence of prevalence and harms in the UK of several novel benzodiazepines and provides advice to the government (ACMD)
Out of harm’s way (PDF)
This document has been written in response to one of eight recommendations in the West Midlands PCC’s Drugs Policy Report (2018), a report that adopts a new approach that is dictated by evidence and compassion and where the emphasis centres on harm reduction to help to lower crime, save money and support communities (West Midlands Police and Crime Commissioner)
Delivering health and care for people who sleep rough (PDF)
This research starts to answer the question of what needs to be in place for the delivery of joined-up services to a population of people sleeping rough – as a system, rather than a discrete collection of services (King’s Fund)
The Special Commission of Inquiry into the Drug ‘Ice’
A list of report sections from NSW, Australia
Framework for Response to the Use of Illicit Substances within Higher Education (PDF)
Based on the Report of the Rapid Response Group (RRG) on Use of Illicit Substances within Higher Education (Ireland)
Drug-related hospital emergency presentations in Europe: update from the Euro-DEN Plus expert network
This report presents the latest findings on drug-related hospital emergencies from a network of sentinel hospitals across Europe. Almost 24 000 emergency presentations were recorded at 32 sentinel hospitals over the first 4 years of the project (EMCDDA)
Access to hepatitis c treatment and care among people who inject drugs: failing people most disproportionately affected
Accurate, high-quality data on hepatitis C continues to be a struggle for countries that are scaling up treatment access, expanding testing services, and developing national hepatitis plans (heoCoalition)
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 12
- Next Page »
